Phase I-II Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation

Trial Profile

Phase I-II Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Peginterferon (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms VEMUPLINT
  • Most Recent Events

    • 18 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 18 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 14 Jan 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top